Current Status of Long Non-Coding RNAs in Human Breast Cancer
AbstractBreast cancer represents a major health burden in Europe and North America, as recently published data report breast cancer as the second leading cause of cancer related death in women worldwide. Breast cancer is regarded as a highly heterogeneous disease in terms of clinical course and biological behavior and can be divided into several molecular subtypes, with different prognosis and treatment responses. The discovery of numerous non-coding RNAs has dramatically changed our understanding of cell biology, especially the pathophysiology of cancer. Long non-coding RNAs (lncRNAs) are non-protein-coding transcripts >200 nucleotides in length. Several studies have demonstrated their role as key regulators of gene expression, cell biology and carcinogenesis. Deregulated expression levels of lncRNAs have been observed in various types of cancers including breast cancer. lncRNAs are involved in cancer initiation, progression, and metastases. In this review, we summarize the recent literature to highlight the current status of this class of long non-coding lncRNAs in breast cancer. View Full-Text
Share & Cite This Article
Cerk, S.; Schwarzenbacher, D.; Adiprasito, J.B.; Stotz, M.; Hutterer, G.C.; Gerger, A.; Ling, H.; Calin, G.A.; Pichler, M. Current Status of Long Non-Coding RNAs in Human Breast Cancer. Int. J. Mol. Sci. 2016, 17, 1485.
Cerk S, Schwarzenbacher D, Adiprasito JB, Stotz M, Hutterer GC, Gerger A, Ling H, Calin GA, Pichler M. Current Status of Long Non-Coding RNAs in Human Breast Cancer. International Journal of Molecular Sciences. 2016; 17(9):1485.Chicago/Turabian Style
Cerk, Stefanie; Schwarzenbacher, Daniela; Adiprasito, Jan B.; Stotz, Michael; Hutterer, Georg C.; Gerger, Armin; Ling, Hui; Calin, George A.; Pichler, Martin. 2016. "Current Status of Long Non-Coding RNAs in Human Breast Cancer." Int. J. Mol. Sci. 17, no. 9: 1485.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.